neuromuscular agents

Summary

Summary: Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.

Top Publications

  1. ncbi OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
    H C Diener
    University of Essen, Germany
    Cephalalgia 30:804-14. 2010
  2. ncbi The structure and mode of action of different botulinum toxins
    J O Dolly
    International Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin, Ireland
    Eur J Neurol 13:1-9. 2006
  3. ncbi OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
    S K Aurora
    Swedish Neuroscience Institute, USA
    Cephalalgia 30:793-803. 2010
  4. ncbi Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
  5. ncbi Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement
    S C Love
    Centre for Musculoskeletal Studies, University of Western Australia, Princess Margaret Hospital, Perth, Western Australia, Australia
    Eur J Neurol 17:9-37. 2010
  6. ncbi Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study
    Gaëtan G Stoquart
    Rehabilitation and Physical Medicine Unit, Universite Catholique de Louvain, Brussels, Belgium
    Arch Phys Med Rehabil 89:56-61. 2008
  7. pmc Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
    Jürgen Frevert
    Merz Pharmaceuticals GmbH, Frankfurt, Germany
    Drugs R D 10:67-73. 2010
  8. ncbi Intrafusal effects of botulinum toxin in post-stroke upper limb spasticity
    C Trompetto
    Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy
    Eur J Neurol 15:367-70. 2008
  9. ncbi Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity
    Petr Kanovsky
    Department of Neurology, Palacky University Medical School University Hospital, IP Pavlova 6, CZ 775 20 Olomouc, Czech Republic
    J Rehabil Med 43:486-92. 2011
  10. ncbi Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay
    Dirk Dressler
    Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Neural Transm 119:13-5. 2012

Research Grants

  1. COMMERCIALIZATION OF GRAPHICAL INTRAVENOUS DRUG DISPLAY
    Noah Syroid; Fiscal Year: 2005
  2. PHYSICAL ACTIVITY INDUCES NEUROTROPHIC FACTORS
    Fernando Gomez Pinilla; Fiscal Year: 2002
  3. Activity-Induced Recovery Following Brain Trauma
    Fernando Gomez Pinilla; Fiscal Year: 2008
  4. NEUROTROPHIN REGULATION IN THE SPINAL CORD
    Fernando Gomez Pinilla; Fiscal Year: 2003
  5. Mechanisms of Vaginal Sling Effects on Continence
    Firouz Daneshgari; Fiscal Year: 2006
  6. Conference--National Urology Resident Female Pelvic Med
    Firouz Daneshgari; Fiscal Year: 2006
  7. NIH Task Force on Childhood Motor Disorders
    Terence Sanger; Fiscal Year: 2006
  8. GENETICS OF PARKINSON DISEASE IN THE AMISH
    Brad Racette; Fiscal Year: 2006
  9. Regulation of Slo Splicing in the Urogenital Systme
    Kelvin Davies; Fiscal Year: 2006
  10. Electrode Array Reanimation of the Paralyzed Larynx
    Marshall Smith; Fiscal Year: 2006

Detail Information

Publications292 found, 100 shown here

  1. ncbi OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
    H C Diener
    University of Essen, Germany
    Cephalalgia 30:804-14. 2010
    ..This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX) for prophylaxis of headaches in adults with chronic migraine...
  2. ncbi The structure and mode of action of different botulinum toxins
    J O Dolly
    International Centre for Neurotherapeutics, Dublin City University, Glasnevin, Dublin, Ireland
    Eur J Neurol 13:1-9. 2006
    ..The widespread cellular distribution of SNAP-25 and the diversity of the toxin's neuronal acceptors are being exploited for other therapeutic applications...
  3. ncbi OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
    S K Aurora
    Swedish Neuroscience Institute, USA
    Cephalalgia 30:793-803. 2010
    ..This is the first of a pair of studies designed to assess efficacy, safety and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine...
  4. ncbi Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
    Daniel Truong
    The Parkinson s and Movement Disorders Institute, Fountain Valley, California 92708, USA
    Mov Disord 20:783-91. 2005
    ..These results confirm previous reports that Dysport (500 units) is safe, effective, and well-tolerated in patients with cervical dystonia...
  5. ncbi Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement
    S C Love
    Centre for Musculoskeletal Studies, University of Western Australia, Princess Margaret Hospital, Perth, Western Australia, Australia
    Eur J Neurol 17:9-37. 2010
    ....
  6. ncbi Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study
    Gaëtan G Stoquart
    Rehabilitation and Physical Medicine Unit, Universite Catholique de Louvain, Brussels, Belgium
    Arch Phys Med Rehabil 89:56-61. 2008
    ..To study the effect of botulinum toxin type A (BTX-A) injection in the rectus femoris on the decreased knee flexion during the swing phase of gait (stiff-knee gait) in people with stroke...
  7. pmc Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®
    Jürgen Frevert
    Merz Pharmaceuticals GmbH, Frankfurt, Germany
    Drugs R D 10:67-73. 2010
    ....
  8. ncbi Intrafusal effects of botulinum toxin in post-stroke upper limb spasticity
    C Trompetto
    Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy
    Eur J Neurol 15:367-70. 2008
    ..This pilot study suggests that some degree of strength and active movement is necessary for the action of BoNT-A on intrafusal fibres...
  9. ncbi Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity
    Petr Kanovsky
    Department of Neurology, Palacky University Medical School University Hospital, IP Pavlova 6, CZ 775 20 Olomouc, Czech Republic
    J Rehabil Med 43:486-92. 2011
    ..To investigate the efficacy and safety of repeated treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity...
  10. ncbi Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay
    Dirk Dressler
    Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Neural Transm 119:13-5. 2012
    ..Identical potency labelling allows easy exchange of both BT drugs in a therapeutic setting, and direct comparison of efficacy, adverse effects and costs...
  11. ncbi A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia
    Elizabeth Maria Aparecida Barasnevicius Quagliato
    Neurology Department, Faculdade de Ciencias Medicas da Universidade Estadual de Campinas, Sao Paulo, Brazil
    Clin Neuropharmacol 33:22-6. 2010
    ..In conclusion, Botox and Prosigne were determined to have equivalent efficacy, safety, and tolerability profiles and dose equivalence for cervical dystonia treatment is 1:1...
  12. pmc Clinical management of spasticity
    A J Thompson
    J Neurol Neurosurg Psychiatry 76:459-63. 2005
  13. ncbi Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy
    Kevin Lowe
    Department of Paediatric Rehabilitation, Sydney Children s Hospital and University of New South Wales, Randwick, Australia
    Dev Med Child Neurol 49:823-9. 2007
    ..8 p=0.00: 2.3 p=0.04). BTX-A was not linked to adverse events, suggesting repeated upper limb injections in children with hemiplegia receiving occupational therapy were safe and effective for improvement of movement and function...
  14. ncbi Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement
    G Sheean
    Neurosciences, Neuromuscular Division, University of California, San Diego, CA 92103 8465, USA
    Eur J Neurol 17:74-93. 2010
    ..More research is needed to resolve many unknown issues of assessment and treatment, using research methods appropriate to the question...
  15. ncbi Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes
    S Cillino
    Dipartimento Universitario di Neuroscienze Cliniche, Sezione di Oftalmologia, Universita degli Studi di Palermo, Palermo, Italy
    Eye (Lond) 24:600-7. 2010
    ....
  16. ncbi Botulinum neurotoxin A: an unusual systemic effect
    Katherine Howell
    Department of Child Development and Rehabilitation, Royal Children s Hospital, Parkville, Victoria, Australia
    J Paediatr Child Health 43:499-501. 2007
    ..Caution is needed in using this treatment in children with severe cerebral palsy and pseudobulbar palsy...
  17. ncbi Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence
    Marissa Barlaan Lukban
    Department of Pediatrics and Neurosciences, University of the Philippines College of Medicine, Manila, Philippines
    J Neural Transm 116:319-31. 2009
    ....
  18. ncbi Management of the upper limb in cerebral palsy
    Terence Y P Chin
    Department of Orthopaedics, Royal Children s Hospital, Parkville, Victoria, Australia
    J Pediatr Orthop B 14:389-404. 2005
    ..Occupational therapy and physiotherapy have small treatment effects alone but are essential adjuncts to medical and surgical management...
  19. ncbi Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A
    Joel Schlessinger
    Advanced Skin Research, Omaha, Nebraska 68144, USA
    Dermatol Surg 37:1434-42. 2011
    ..OBJECTIVE To determine onset of response based on participant assessments recorded from days 1 through 7...
  20. ncbi Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity
    Apostolos Apostolidis
    Department of Uro Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Eur Urol 49:644-50. 2006
    ..The efficacy of the treatment exceeds that expected from simple detrusor muscle paralysis, however, and its effect of reducing urgency is greatly welcomed by patients...
  21. ncbi Botulinum toxin: mechanisms of action
    Dirk Dressler
    Department of Neurology, Rostock University, Rostock, Germany
    Eur Neurol 53:3-9. 2005
    ..Reduction of formalin-induced pain suggests direct analgesic BT effects possibly mediated by blockade of substance P, glutamate and calcitonin gene-related peptide...
  22. ncbi Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm
    P Roggenkämper
    Department of Ophthalmology, University of Bonn, Wiesbaden, Germany
    J Neural Transm 113:303-12. 2006
    ..These data show that NT 201* is an effective and safe treatment for patients suffering from blepharospasm...
  23. ncbi Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain
    Wei Cheong Ngeow
    Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:e47-50. 2010
    ..The patient was pain free with a maintenance dose of 200 mg carbamazepine daily for about 1 year, after which she elected to undergo stereotactic gamma knife radiosurgery when pain recurred at the external nasal region...
  24. ncbi Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia
    Daniel Truong
    The Parkinson s and Movement Disorder Institute, 9940 Talbert Avenue, 204, Fountain Valley, CA 92708, USA
    Parkinsonism Relat Disord 16:316-23. 2010
    ..These results confirm that Dysport (500 units) is safe, effective, and well-tolerated in patients with CD...
  25. ncbi European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity
    Andre Reitz
    Neuro Urology, Swiss Paraplegic Center, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland
    Eur Urol 45:510-5. 2004
    ..To present a comprehensive experience with botulinum-A toxin (BTA) injected into the detrusor muscle in patients with spinal cord injuries/diseases causing neurogenic incontinence...
  26. ncbi Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity
    R L Rosales
    Department of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines
    J Neural Transm 115:617-23. 2008
    ..In this article, we summarized the data of randomized, placebo-controlled, double- blind trials and conducted a meta-analysis to assess if BoNTA is an adequate treatment for spasticity following stroke...
  27. ncbi Botulinum toxin A injections in children: technique and dosing issues
    Douglas Kinnett
    Division of Pediatric Rehabilitation, Departments of Pediatrics and Physical Medicine and Rehabilitation, The Cincinnati Children s Hospital Medical Center and University of Cincinnati, Ohio 45229, USA
    Am J Phys Med Rehabil 83:S59-64. 2004
    ..Use of electromyographic, electrical stimulation, or ultrasound guidance is employed in children for difficult to locate individual muscle groups. Use of sedation also varies between medical centers...
  28. ncbi Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis
    Maik Ellies
    Department of Otorhinolaryngology Head and Neck Surgery, University of Gottingen, Robert Koch Strasse 40, D 37075 Gottingen, Germany
    Laryngoscope 114:1856-60. 2004
    ..A controlled follow-up study documenting efficiency, possible side effects, and duration of the effect of treatment was also performed...
  29. ncbi Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke
    Martin K Childers
    Dept of Physical Medicine and Rehabilitation, University of Missouri at Columbia, One Hospital Drive, DCO 46 00, Columbia, MO 65212, USA
    Arch Phys Med Rehabil 85:1063-9. 2004
    ..To test the hypothesis that intramuscular (IM) botulinum toxin type A (BTX) reduces excessive muscle tone in a dose-dependent manner in the elbow, wrist, and fingers of patients who experience spasticity after a stroke...
  30. ncbi Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review
    Gilles Karsenty
    Hopital Sainte Marguerite, Marseille, France
    Eur Urol 53:275-87. 2008
    ....
  31. ncbi Impaired sensorimotor integration in focal hand dystonia patients in the absence of symptoms
    C Carolyn Wu
    Department of Psychology, Research Centre for Cognitive Neuroscience, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    J Neurol Neurosurg Psychiatry 81:659-65. 2010
    ..Thus, in order to characterise impairments in patients with FHD during movements that do not induce dystonic symptoms, we investigated the neural correlates of externally paced finger tapping movements...
  32. ncbi Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study
    Shu Fen Sun
    National Yang Ming University School of Medicine, Taiwan
    Neurorehabil Neural Repair 24:34-41. 2010
    ..The aim was to investigate whether combined BtxA and mCIMT would improve spasticity and upper extremity motor function more than BtxA plus conventional rehabilitation in chronic stroke patients with upper extremity spasticity...
  33. ncbi OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine
    James E Frampton
    Adis, Auckland, New Zealand
    Drugs 72:825-45. 2012
    ..Overall, onaBoNTA offers a beneficial, acceptably tolerated and potentially convenient option for the management of this highly disabling condition, for example in patients who are refractory to oral medications used for prophylaxis...
  34. ncbi Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial
    Peter H Jongerius
    Department of Rehabilitation, University Medical Centre St Radboud, PO Box 9101 6500HB, Nijmegen 720, Netherlands
    Pediatrics 114:620-7. 2004
    ..To investigate the clinical effectiveness of botulinum neurotoxin type A (BoNT) to reduce drooling in children with cerebral palsy (CP)...
  35. ncbi Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial
    Lynne Turner-Stokes
    King s College London School of Medicine, London, Middlesex, HA1 3UJ, United Kingdom
    J Rehabil Med 42:81-9. 2010
    ..To examine goal attainment scaling for evaluation of treatment for upper limb post-stroke spasticity with botulinum toxin-A...
  36. ncbi Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence
    Brigitte Schurch
    Spinal Cord Injury Center, University Hospital Balgrist, Zurich, Switzerland
    Eur Urol 52:850-8. 2007
    ..To evaluate the impact of botulinum toxin type A (BoNTA) on health-related quality of life in patients with neurogenic urinary incontinence (UI) using the Incontinence Quality of Life questionnaire (I-QOL)...
  37. ncbi Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins
    D Dressler
    Movement Disorders Section, Department of Neurology, Hannover Medical School, Hannover, Germany
    Eur J Neurol 19:385-9. 2012
    ..Lack of reported cases of antibody-induced therapy failure (ABF), as to date, support the hypothesis of an improved antigenicity...
  38. pmc Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy
    T Ubhi
    Academic Department of Paediatrics and Child Health, University of Leeds, UK
    Arch Dis Child 83:481-7. 2000
    ..Intramuscular botulinum toxin (BT-A) offers a targeted form of therapy to reduce spasticity in specific muscle groups...
  39. ncbi Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis
    Shahid Khan
    Department of Uro Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom
    J Urol 185:1344-9. 2011
    ..We studied the effect of repeat detrusor botulinum neurotoxin type A injections on urinary symptoms, health and quality of life in patients with refractory neurogenic detrusor overactivity secondary to multiple sclerosis...
  40. ncbi Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis
    Eduardo Cardoso
    Division of Neurology and Epidemiology, Federal University of Bahia, Salvador, BA, Brazil
    Arq Neuropsiquiatr 63:30-3. 2005
    ..The results show a statistical superiority of BTX-A ov%r placebo on reducing muscle tone by the Modified Ashworth Scale (WMD= 0.95 [0.74 to 1.17]) in patients with post-stroke upper limb spasticity...
  41. ncbi Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines
    Gerhard Sattler
    Rosenpark Klinik, Darmstadt, Germany
    Dermatol Surg 36:2146-54. 2010
    ..Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also known as NT 201, is a new botulinum toxin type A (150 kDa) that is free from complexing proteins...
  42. ncbi Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke
    Allison Brashear
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202, USA
    N Engl J Med 347:395-400. 2002
    ..Spasticity is a disabling complication of stroke, and it is uncertain whether intramuscular injections of botulinum toxin type A reduce disability in persons with spasticity of the wrist and fingers after a stroke...
  43. ncbi Botulinum toxin type A in post-stroke upper limb spasticity
    Ryuji Kaji
    Department of Clinical Neuroscience, Institute of Health Biosciences, Tokushima University Graduate School, Tokushima City, Tokushima, Japan
    Curr Med Res Opin 26:1983-92. 2010
    ..To evaluate the efficacy and safety of one-time injections of botulinum toxin type A (BoNTA) in Japanese patients with post-stroke upper limb spasticity...
  44. ncbi Beneficial effects of botulinum toxin type a for patients with painful tic convulsif
    Federico Micheli
    Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina
    Clin Neuropharmacol 25:260-2. 2002
    ..Further infiltrations were given every 12 weeks following the same response pattern. This observation further validates the increasing role of botulinum toxin in pain management...
  45. ncbi Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation
    Terence Y P Chin
    Department of Orthopaedics, Royal Children s Hospital, Flemington Road, Parkville 3052, Victoria, Australia
    J Pediatr Orthop 25:286-91. 2005
    ..Further study is needed to determine whether more accurate injecting will lead to better functional outcomes and more efficient use of botulinum toxin A...
  46. pmc Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A
    Alain P Yelnik
    AP HP, GH Lariboisiere F Widal, Physical Medicine and Rehabilitation Department, 200 rue du Faubourg Saint Denis, 75010 Paris, France
    J Neurol Neurosurg Psychiatry 78:845-8. 2007
    ....
  47. pmc Multilevel botulinum toxin type a as a treatment for spasticity in children with cerebral palsy: a retrospective study
    Ece Unlu
    Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Clinic of Physical Medicine and Rehabilitation Ankara, Turkey
    Clinics (Sao Paulo) 65:613-9. 2010
    ..The treatment of spasticity with botulinum toxin type A (BTX-A) is a well-established option in the interdisciplinary management of spasticity, providing focal reductions in muscle tone in cerebral palsy patients...
  48. ncbi The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling
    Duco Steenbeek
    Rehabilitation Centre Breda, The Netherlands
    Clin Rehabil 19:274-82. 2005
    ..To measure the effect of botulinum toxin type A (BTX-A) treatment in children with cerebral palsy with regard to individual goals concerning functional abilities, using goal attainment scaling...
  49. ncbi The role of botulinum toxin A in augmentation of the effect of recession and/or resection surgery
    Seyhan B Ozkan
    Department of Ophthalmology, Adnan Menderes University, Aydin, Turkey
    J AAPOS 10:124-7. 2006
    ..The aim of this study is to assess the effectiveness of intraoperative botulinum toxin A (BTA) injection as an adjunct to the surgical treatment of large-angle esotropia or exotropia...
  50. ncbi A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
    C Collin
    Royal Berkshire and Battle Hospitals NHS Trust, London Road, Reading, Berkshire RG1 5AN, UK
    Neurol Res 32:451-9. 2010
    ..Muscle spasticity is common in multiple sclerosis (MS), occurring in more than 60% of patients...
  51. ncbi Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement
    I Novak
    Cerebral Palsy Institute, School of Medicine, University of Notre Dame, Darlinghurst, Sydney, NSW, Australia
    Eur J Neurol 17:94-108. 2010
    ..More research is needed to answer questions about safety and efficacy in secondary spastic neck dystonia, effective adjunctive therapy, dosing and favourable injection techniques...
  52. ncbi Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study
    J D Rollnik
    Department of Neurology and Clinical Neurophysiology, Medical School of Hannover, Germany
    Headache 40:300-5. 2000
    ..CONCLUSIONS: The findings of our study strongly support the hypothesis that peripheral mechanisms, such as increased muscle tenderness, only play a minor role in the pathogenesis of tension-type headache...
  53. ncbi Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy
    Claire T Lundy
    Evelina Children s Hospital, Lambeth Palace Road, London, UK
    Dev Med Child Neurol 51:705-10. 2009
    ..Anecdotal evidence suggests a reduction in pain after this treatment in children who had pain localized to a displaced hip joint. We report on our current clinical practice...
  54. ncbi Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study
    Welf Prager
    Dermatologikum Hamburg, Hamburg, Germany
    Dermatol Surg 36:2155-60. 2010
    ..This is the first double-blind, randomized, proof-of-concept study to compare the clinical effectiveness of botulinum toxin type A (BoNTA) free of complexing proteins with a BoNTA complex (BTXCo) in the treatment of crow's feet...
  55. ncbi Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder
    H Schulte-Baukloh
    Department of Urology, St Hedwig Hospital, Grosse Hamburger Strasse 5 11, 10115 Berlin, Germany
    Eur Urol 44:139-43. 2003
    ..Surgery, such as bladder augmentation, is often necessary in such cases. To obviate surgery in these high-risk children, we investigated the use of detrusor injection of botulinum-A toxin (Botox)...
  56. ncbi Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm
    A Conte
    Department of Neurological Sciences, Sapienza University of Rome, Rome, Italy
    Eur J Neurol 17:449-55. 2010
    ..The second aim was to assess the safety of BonT-A by investigating whether BonT-A injection alters the excitability of blink reflex circuits in the brainstem...
  57. ncbi Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children
    A Marte
    Pediatric Surgery Second University of Naples, Pediatrics, Naples, Italy
    Eur J Pediatr Surg 20:153-7. 2010
    ..We describe our experience with botulinum-A toxin (BTX-A) in children presenting idiopathic overactive bladder (OAB) refractory to anticholinergic drugs...
  58. ncbi Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review
    Xavier Game
    Hopital Rangueil, Toulouse, France
    J Pediatr Urol 5:156-64. 2009
    ....
  59. ncbi Botulinum toxin: dosing and dilution
    Gerard E Francisco
    Physical Medicine and Rehabilitation Alliance, Baylor College of Medicine University of Texas, Houston, Texas, USA
    Am J Phys Med Rehabil 83:S30-7. 2004
    ..This article will review important articles and selected abstracts on the use of botulinum toxin, specifically for spastic hypertonia in adults, with emphasis on current clinical practices as they relate to dosing and dilution...
  60. pmc Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience
    Ivano Farinelli
    Department of Clinical Sciences, Sapienza University of Rome, 2nd School of Medicine, Sant Andrea Hospital, Via di Grottarossa 1035, I 00189, Rome, Italy
    J Headache Pain 7:407-12. 2006
    ..In conclusion, BoNT-A therapy appears to be an efficacious new therapeutic choice in the prophylaxis of CDH, especially for patients not responding to previous prophylactic treatments...
  61. ncbi Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache
    Ninan T Mathew
    Houston Headache Clinic, Houston, TX 77004, USA
    Headache 48:194-200. 2008
    ..To evaluate predictors of response to botulinum toxin type A (BoNTA; BOTOX, Allergan Inc., Irvine, CA, USA) in patients with chronic daily headache (CDH)...
  62. ncbi Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia
    Allison Brashear
    Department of Neurology, Indiana University Medical Center, 550 University Boulevard, Room 6620, Indianapolis, IN 46202, USA
    Adv Ther 22:49-55. 2005
    ..48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation...
  63. pmc Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
    M R Delgado
    University of Texas Southwestern Medical Center, Dallas, USA
    Neurology 74:336-43. 2010
    ..To evaluate published evidence of efficacy and safety of pharmacologic treatments for childhood spasticity due to cerebral palsy...
  64. ncbi Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study
    Wendelin Blersch
    Department of Neurology, University of Regensburg, Universitatsstrasse 84, 93053 Regensburg, Germany
    J Neurol Sci 205:59-63. 2002
    ..The study shows that there is no direct peripheral antinociceptive effect of BoNT/A in humans. The efficacy of BoNT/A in various pain syndromes must be explained by other pathways such as chemodenervation or anti-inflammatory effects...
  65. pmc Botulinum toxin in clinical practice
    J Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurol Neurosurg Psychiatry 75:951-7. 2004
    ..Long term experience with this agent suggests that it is an effective and safe treatment not only for approved indications but also for an increasing number of off-label indications...
  66. ncbi Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group
    L A Koman
    Department of Orthopaedic Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1070, USA
    J Pediatr Orthop 20:108-15. 2000
    ..Patients in the BTX group demonstrated improved gait function and partial denervation of the injected muscle. No serious adverse events were reported...
  67. pmc Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument
    J Muller
    University Hospital of Neurology, Innsbruck, Austria University Hospital of Psychiatry, Innsbruck, Austria
    J Neurol Neurosurg Psychiatry 75:749-53. 2004
    ..To develop and test a questionnaire for measuring quality of life in patients with craniocervical dystonia...
  68. ncbi Recommendations for the use of botulinum toxin type A in the management of cerebral palsy
    H K Graham
    Department of Orthopaedic Surgery, Royal Children s Hospital, Parkville, Flemington Road, Melbourne, Australia
    Gait Posture 11:67-79. 2000
    ..The importance of adjunctive physiotherapy, orthoses and casting is also stressed...
  69. ncbi A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research
    A Cusick
    College of Science and Health, University of Western Sydney, Australia
    Pediatr Rehabil 9:149-57. 2006
    ..To investigate the relative utility of Canadian Occupational Performance Measure (COPM) (adapted for children) and Goal Attainment Scaling (GAS) as outcome measures for paediatric rehabilitation...
  70. pmc High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy
    Allison W Willis
    Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
    Dev Med Child Neurol 49:818-22. 2007
    ..All doses were associated with a significant increase in passive range of motion using the Tardieu scale. We conclude that higher dose BTX-A is safe in children with a spectrum of CP phenotypes and are well tolerated over time...
  71. ncbi Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence
    Joachim Grosse
    Department of Urology, Berufsgenossenschaftliche Unfallklinik Murnau, Murnau, Germany
    Eur Urol 47:653-9. 2005
    ..When the patients develop botulinum resistance, subsequent injections might be less effective. Repeat injections in patients with severe neurogenic detrusor overactivity and incontinence were studied...
  72. ncbi Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy
    Krishant Naidu
    The Royal Children s Hospital, Melbourne, Victoria, Australia
    Dev Med Child Neurol 52:139-44. 2010
    ..We studied the incidence of incontinence and respiratory events in children with cerebral palsy who received injections of botulinum toxin A (BoNT-A)...
  73. ncbi European consensus table on the use of botulinum toxin type A in adult spasticity
    Jorg Wissel
    Kliniken Beelitz GmbH, Clinical Department of Neurological Rehabilitation, Beelitz Heilstaetten, Germany
    J Rehabil Med 41:13-25. 2009
    ....
  74. ncbi Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Oliver Lange
    Institute for Pharmacology and Toxicology, Hannover Medical University, Hannover, Germany
    Clin Neuropharmacol 32:213-8. 2009
    ..To explore this issue, we evaluated levels of NAbs in a large selected cohort of secondary nonresponders to BoNT-A using the highly sensitive mouse phrenic nerve-hemidiaphragm assay...
  75. ncbi Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm
    Bettina Wabbels
    Department of Ophthalmology, University of Bonn, Abbestr 2, 53127, Bonn, Germany
    J Neural Transm 118:233-9. 2011
    ..67 points on the BSDI mean item score. No significant differences between products were noted in PGA and adverse events at the doses used in this study...
  76. ncbi Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens
    J Slawek
    Department of Neurosurgery, Division of Movement Disorders and Functional Neurosurgery, Medical University, ul Debinki 7, 80 211, Gdansk, Poland
    Neurol Sci 26:32-9. 2005
    ..Individualised BTX-A injection regimens may be an effective, reversible and safe new treatment option for patients with spasticity. Nevertheless, functional improvement may be reached only in selected patients...
  77. ncbi Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity
    Anthony Ward
    North Staffordshire Rehabilitation Unit, The Hayward, Stoke on Trent, Staffordshire, UK
    J Rehabil Med 37:252-7. 2005
    ..The objective of this study was to compare the cost-effectiveness and outcomes of oral therapy vs. botulinum toxin type A treatment strategies in patients with flexed wrist/clenched fist spasticity...
  78. ncbi Xeomin is free from complexing proteins
    Jürgen Frevert
    Merz Pharmaceuticals GmbH, Hermannswerder Haus 15, 14473 Potsdam, Germany
    Toxicon 54:697-701. 2009
    ..Whereas competing product must be stored refrigerated, Xeomin is stable for 3years at room temperature...
  79. ncbi Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain
    Danièle Ranoux
    Services de Neurologie, Neurochirurgie et Soins Palliatifs, Centre Hospitalier Universitaire de Limoges, Limoges, France
    Ann Neurol 64:274-83. 2008
    ..Botulinum toxin type A (BTX-A) has been reported to have analgesic effects independent of its action on muscle tone, possibly by acting on neurogenic inflammation. Such a mechanism may be involved in peripheral neuropathic pain...
  80. ncbi Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial
    Eric J Pappert
    Solstice Neurosciences, Inc, Malvern, Pennsylvania, USA
    Mov Disord 23:510-7. 2008
    ..Mild dry mouth was more frequent with BoNT-B but there were no differences for moderate/severe dry mouth. In this study, both BoNT-A and B were shown to be effective and safe for the treatment of toxin-naive CD subjects...
  81. ncbi Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections
    Jaroslaw Slawek
    Department of Neurological Psychiatric Nursing, Medical University, Gdansk, Poland
    Funct Neurol 22:95-100. 2007
    ..Cervical dystonia has a marked impact on HRQL and treatment with BTX-A injections has a beneficial effect, seen both in objective and in subjective measures. Depression in CD patients is a main predictor of worse HRQL...
  82. ncbi A summary of spasticity management--a treatment algorithm
    A B Ward
    North Staffs Rehabilitation Centre, Haywood and Stanfield Hospital, Department of Rehabilitation Medicine, Stoke on Trent, UK
    Eur J Neurol 9:48-52; dicussion 53-61. 2002
    ..The evidence base for much of what is done is not strong and this summary examines the activities of proven value and of consensus view...
  83. ncbi Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm
    Angelo Quartarone
    Department of Neurosciences, University of Messina, 98125 Messina, Italy
    J Neurosci 26:716-21. 2006
    ..BTX treatment removes the latter and restores plasticity toward normal values. Our results support the concept that maladaptive reorganization contributes to the pathophysiology of focal dystonias...
  84. ncbi Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study
    Albert Marchetti
    Thomson Health Economics Research, Secaucus, New Jersey, USA
    Mov Disord 20:937-44. 2005
    ..Results are consistent with United Kingdom labeling for botulinum toxins stating that units of different serotype A toxins are not interchangeable and simple dose-conversion factors are not applicable...
  85. ncbi The treatment of cerebral palsy: What we know, what we don't know
    Murray Goldstein
    UCP Research and Educational Foundation, Washington, DC 20036, USA
    J Pediatr 145:S42-6. 2004
    ..Data on treatment compatible with evidence-based medicine are now being collected...
  86. ncbi Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models
    S Marinelli
    CNR, Institute of Neuroscience, Via del Fosso di Fiorano 64, 00143 Roma, Italy
    Neuroscience 171:316-28. 2010
    ..These results may have important implications in the therapy of neuropathic pain...
  87. ncbi Do the unintended actions of botulinum toxin at distant sites have clinical implications?
    Antonio Curra
    Department of Neurological Sciences and A Fiorini Hospital, Terracina, LT, Sapienza, University of Rome, Polo Pontino, Italy
    Neurology 72:1095-9. 2009
    ..Whatever the mechanism, the lack of deleterious central effects implies that while research into action mechanisms continues, physicians can safely use BT for therapy...
  88. ncbi Safety of botulinum toxin type A in children younger than 2 years
    Samuel Ignacio Pascual-Pascual
    Pediatric Neurology Service, University Hospital La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
    Eur J Paediatr Neurol 13:511-5. 2009
    ..Botulinum toxin type A (BoNT-A) has been used in many indications and is licensed for the treatment of spasticity in children older than 2 years. However, there are few reports of BoNT-A treatment in patients younger than 2 years of age...
  89. pmc Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation
    Kristie Bjornson
    Department of Rehabilitation Medicine, Children s Hospital and Regional Medical Center, MPW 8 3, 4800 Sand Point Way NE, Seattle, WA 98105, USA
    Pediatrics 120:49-58. 2007
    ..Interpretation of the literature is difficult because of the paucity of reliable measures of spasticity and challenges with measuring meaningful functional changes in children with disabilities...
  90. pmc Migraine prophylaxis with botulinum toxin A is associated with perception of headache
    Rami Burstein
    Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Toxicon 54:624-7. 2009
    ..Imploding/ocular migraine headache is more likely than exploding headache to be prevented by prophylactic BTX-A treatment. Further validation of this principle should await large-scale prospective, placebo-controlled studies...
  91. ncbi The impact of blepharospasm and cervical dystonia on health-related quality of life and depression
    J Muller
    Department of Neurology, Innsbruck University Hospital, Anichstr 35, Austria
    J Neurol 249:842-6. 2002
    ....
  92. ncbi Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
    Cidronio Albavera-Hernández
    National Institute of Public Health, Mexican Social Security Institute
    Clin Rehabil 23:394-407. 2009
    ..To assess the safety of botulinum toxin type A for children with cerebral palsy using data from randomized clinical trials...
  93. ncbi Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection
    H Schulte-Baukloh
    Department of Urology, St Hedwig Hospital, Medical School of Charité Universitätsmedizin Berlin, Berlin, Germany hschultebaukloh hotmail com
    Urol Int 87:434-8. 2011
    ..In a prospective study, we analyzed patient serum for BoNT/A antibodies (BoNT/A-AB) as a possible cause of therapy failure...
  94. ncbi Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: a preliminary report
    Khalid Fouda Neel
    Division of Urology, Department of Surgery 37, King Saud University, King Khalid University Hospital, POB 7805, Riyadh 11472, Kingdom of Saudi Arabia
    J Pediatr Urol 4:124-6. 2008
    ..We also evaluated whether this combined therapy can lower intravesical pressure, increase bladder capacity, gain social continence and protect the upper tract from recurrent urinary tract infection...
  95. ncbi Effects of botulinum toxin A in ambulant adults with spastic cerebral palsy: a randomized double-blind placebo controlled-trial
    Grethe Maanum
    Sunnaas Rehabilitation Hospital, Bjørnemyr, Nesoddtangen, Norway
    J Rehabil Med 43:338-47. 2011
    ..This study aimed to assess short-term effects of botulinum toxin A in ambulant adults with spastic cerebral palsy...
  96. ncbi Disabling overactivity of the extensor hallucis longus after stroke: clinical expression and efficacy of botulinum toxin type A
    Alain P Yelnik
    Physical Medicine and Rehabilitation Department, GH Lariboisière Fernand Widal, Paris, France
    Arch Phys Med Rehabil 84:147-9. 2003
    ..To describe the clinical characteristics of persistent extension of the great toe related to overactivity of the extensor hallucis longus (EHL) after a stroke and to explore the efficacy of treatment with botulinum toxin type A...
  97. ncbi Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis
    M Giovannelli
    Multiple Sclerosis Centre, S Andrea Hospital, University of Rome La Sapienza, Rome, Italy
    Clin Rehabil 21:331-7. 2007
    ..To determine whether additional physiotherapy increases botulinum toxin type A effects in reducing spasticity in patients with multiple sclerosis...
  98. ncbi Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity
    Edward M Goldstein
    Child Neurology Associates, Children s Healthcare of Atlanta at Scottish Rite Children s Medical Center, Marcus Institute Division of Child Neurology, Atlanta, GA 30342, USA
    J Child Neurol 21:189-92. 2006
    ..High-dose botulinum toxin type A is safe for the treatment of spasticity in children and young adults...
  99. ncbi Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review
    Ulrike Ryll
    Department of Epidemiology, Caphri Research Institute, Maastricht University, Maastricht, The Netherlands
    Dev Med Child Neurol 53:210-6. 2011
    ..To assess treatment effects of botulinum toxin type A (BoNT-A) on walking of children with leg spasticity due to cerebral palsy (CP) compared with usual care...
  100. ncbi Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients
    Ulla Bergfeldt
    Rehabilitation Medicine University Clinic, Karolinska Institutet, Stockholm, Sweden
    J Rehabil Med 38:166-71. 2006
    ..Analysis of the effects of a comprehensive focal spasticity program in adult patients...
  101. ncbi [Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia]
    P Denys
    Service de Medecine Physique et de Readaptation, Hopital Raymond Poincare, AP HP, Faculte de Medecine Paris Ile de France Ouest, 104, Boulevard Raymond Poincare, 92380 Garches, France
    Ann Readapt Med Phys 46:326-8. 2003
    ..To determinate the efficacy of botulinum toxin to treat refractory urinary incontinence due to bladder hyperreflexia...

Research Grants58

  1. COMMERCIALIZATION OF GRAPHICAL INTRAVENOUS DRUG DISPLAY
    Noah Syroid; Fiscal Year: 2005
    ..Phase II: We plan to incorporate additional drug models (premedicatipns, inhalation gases and neuromuscular agents) and evaluate the graphical PKPD display's utility in the operating room...
  2. PHYSICAL ACTIVITY INDUCES NEUROTROPHIC FACTORS
    Fernando Gomez Pinilla; Fiscal Year: 2002
    ..Thirdly, the PI will determine whether locomotor deficit caused by degeneration of large muscle afferents (by using high doses of pyridoxine) can be countered by daily locomotion induction of neurotrophins. ..
  3. Activity-Induced Recovery Following Brain Trauma
    Fernando Gomez Pinilla; Fiscal Year: 2008
    ..Therefore, the unique aspect of our proposal is to evaluate experience as a modulator of neuronal plasticity that can be used to enhance functional recovery following TBI. ..
  4. NEUROTROPHIN REGULATION IN THE SPINAL CORD
    Fernando Gomez Pinilla; Fiscal Year: 2003
    ..abstract_text> ..
  5. Mechanisms of Vaginal Sling Effects on Continence
    Firouz Daneshgari; Fiscal Year: 2006
    ..The long-term goal of this proposal is to expand the findings of this project into an R01 application in order to translate our findings into relevant clinical studies. [unreadable] [unreadable]..
  6. Conference--National Urology Resident Female Pelvic Med
    Firouz Daneshgari; Fiscal Year: 2006
    ..abstract_text> ..
  7. NIH Task Force on Childhood Motor Disorders
    Terence Sanger; Fiscal Year: 2006
    ..The ultimate objective is to improve the functional abilities and societal participation of children with motor disorders. ..
  8. GENETICS OF PARKINSON DISEASE IN THE AMISH
    Brad Racette; Fiscal Year: 2006
    ..abstract_text> ..
  9. Regulation of Slo Splicing in the Urogenital Systme
    Kelvin Davies; Fiscal Year: 2006
    ..This research project will allow Dr. Davies to develop a thorough understanding of urogenital physiology, while at the same time allowing him to utilize his experience in molecular biology. ..
  10. Electrode Array Reanimation of the Paralyzed Larynx
    Marshall Smith; Fiscal Year: 2006
    ..Nerve samples will be harvested and studied to examine the effects of the implanted array on RLN fibers. [unreadable] [unreadable]..
  11. Expiratory muscle training in patients with Parkinson's
    Christine Sapienza; Fiscal Year: 2006
    ..The goals of the grant meet the mission of the R21. Its potential impact is high due to the therapy program's innovative nature and potential cost-effectiveness as a treatment approach. ..
  12. Chronic Prostatitis Collaborative Research Network
    Rodney Anderson; Fiscal Year: 2007
    ..abstract_text> ..
  13. ALPHA-2 ADRENERGIC CONTROL OF COLONIC FUNCTION IN IBS
    Michael Camilleri; Fiscal Year: 2007
    ..abstract_text> ..
  14. Cannabinoid Mechanisms in Human Gastrointestinal Motor and Sensory Functions
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ..These actions may be relevant to develop new treatments for IBS. The studies will also provide further understanding of the potential of medications like medical marijuana on stomach function that may be relevant to appetite control. ..
  15. The Pathophysiology of CMT2A in Cell and Animal Models
    Stephan Zuchner; Fiscal Year: 2010
    ..3) There is no treatment available for axonal CMT patients, but recent studies based on mouse models for demyelinating neuropathies revealed for the first time promising results for future treatment. ..
  16. Somatomedin: Autologous Regulator of Bone Formation
    Ernesto Canalis; Fiscal Year: 2008
    ..These investigations should clarify the role of CHOP in bone cell differentiation and function. [unreadable] [unreadable]..
  17. Limbic & Motor System Interaction in Laryngeal Function
    Douglas Van Daele; Fiscal Year: 2008
    ..It will promote a better understanding of how speech is acquired and generated at the cortical level, of voice disorders such as spasmodic dysphonia, of the focal dystonias, and of speech recovery after brain injury. ..
  18. OUTCOME MEASURES FOR CLINICAL TRIALS IN STRABISMUS
    Jonathan Holmes; Fiscal Year: 2008
    ..Ultimately this research will result in better quality of life for patients with strabismus. ..
  19. ALPHA 2 ADRENERGIC CONTROL IN IRRITABLE BOWEL SYNDROME
    Michael Camilleri; Fiscal Year: 2008
    ..Significance: This project will characterize pharmacogenetic mechanisms determining the response to clonidine through studies of candidate genes that control alpha2-adrenoreceptor function and norepinephrine transport in IBS. ..
  20. fMRI Predictor Model for Stroke Locomotor Rehabilitation
    Bruce Dobkin; Fiscal Year: 2008
    ..The study is a step toward using fMRI as a tool to develop theory- and evidencebased practices that lessen disabilities after stroke. [unreadable] [unreadable] [unreadable]..
  21. Leupeptin in a Canine Model of Duchenne Muscular Dystrophy
    MARTIN CHILDERS; Fiscal Year: 2006
    ..Specific Aim #4b: Compare lean body muscle mass and calpain activity between leupeptin and placebo-treated GRMD dogs. ..
  22. Collaborative Urological Research in Spinal Cord Injury
    Michael Chancellor; Fiscal Year: 2005
    ..f. of fully equipped laboratory and clinical space. This Program is important for the advancement of patient care and basic understanding of SCI and neurogenic bladder dysfunction. ..
  23. Arm Kinematics in Hyperkinetic Cerebral Palsy
    Terence Sanger; Fiscal Year: 2005
    ..Hlatky will guide the design and implementation of clinical trials and outcome measure validation. The proposal includes coursework in cellular and molecular neurobiology and in the design of clinical research studies. ..
  24. Childhood Motor Impairment and Assisted Communication
    Terence Sanger; Fiscal Year: 2004
    ....
  25. EXTREMITY CONSTRAINT INDUCED THERAPY EVALUATION (EXCITE)
    Steven Wolf; Fiscal Year: 2004
    ..Primary outcome measures are a laboratory motor function test and amount of extremity use in the real world setting. Changes in psychosocial functioning will also be measured. ..
  26. Deciphering toxin neutralization by oligoclonal antibody
    James Marks; Fiscal Year: 2003
    ..In addition, this approach would be applicable to four of the other Class A agents (anthrax, smallpox, plague, and hemorrhagic fever viruses). ..
  27. Vcsa1 (hSMR3A) as a Marker for Diabetes
    Kelvin Davies; Fiscal Year: 2008
    ..The final aim will be to determine expression levels of hSMR3A protein from diabetic and non-diabetic patients (in saliva, blood and corporal samples) as an indicator of vascular health. [unreadable] [unreadable] [unreadable]..
  28. UROLOGIC TRAINING PROGRAM FOR PHYSICIANS AND SCIENTISTS
    Michael Chancellor; Fiscal Year: 2003
    ..The trainees facilities can serve more fellows than will be funded by this training proposal. All the training can be carried out in the more than 55,000 square feet of fully equipped laboratory space available. ..
  29. PATHOGENESIS OF RETINOPATHY OF PREMATURITY
    Jonathan Holmes; Fiscal Year: 2003
    ....
  30. SELECTIVE REMOVAL OF EXTRAOCULAR MUSCLE
    Alan Scott; Fiscal Year: 2002
    ..Aim 6 represents human pilot studies needed for design of clinical trials for the therapy developed in this proposal. ..
  31. ANGER, SYMPTOM SPECIFIC REACTIVITY AND CHRONIC PAIN
    John Burns; Fiscal Year: 2002
    ..Documenting a link between anger and LP reactivity will give empirical justification for targeting problematic anger among CLPB patients, and will provide principles on which to found new intervention strategies. ..
  32. MUSCLE RESPONSE TO STRESS IN CANINE MUSCULAR DYSTROPHY
    MARTIN CHILDERS; Fiscal Year: 2002
    ..It is anticipated that findings will improve the understanding of how dystrophic muscle responds to physical stress resulting in improved treatment for patients with Duchenne muscular dystrophy. ..
  33. Repressive Style, suppression and chronic Pain
    John Burns; Fiscal Year: 2004
    ..Moreover, findings should provide theoretical principles on which to found new intervention strategies (e.g., "regulating" suppression by engaging in cognitive exercises). ..
  34. Neural control of abnormal movement
    Terence Sanger; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  35. The Role of Vsca1 in Erectile Function
    Kelvin P Davies; Fiscal Year: 2010
    ..Vcsal/hSMR3A expression might also be used as a non-subjective marker of erectile function. ..
  36. Gene Expression in Inflammatory Myopathies
    Steven Greenberg; Fiscal Year: 2005
    ..This work may provide further diagnostic approaches to these disorders and contribute to the understanding of their pathogenesis. ..
  37. PKC ALTERATIONS IN LUT DYSFUNCTION
    Firouz Daneshgari; Fiscal Year: 2004
    ..abstract_text> ..
  38. Molecular And Genetic Analysis Of Autosomal Dominant Spastic Paraplegia
    Stephan Zuchner; Fiscal Year: 2011
    ..We strongly believe that only such an integrated approach - clinical, genetic, and molecular/functional - will yield significant progress in the understanding of HSP. ..
  39. Epidemilogy of Parkinsonism in Welders
    Brad A Racette; Fiscal Year: 2011
    ..The cohort assembled will provide unique opportunities for future research projects into gene-environment interactions and exposure related neuroimaging changes. ..
  40. Assessment of Altered Function in Diabetic Bladder
    Firouz Daneshgari; Fiscal Year: 2005
    ....
  41. PHONATION AND PHONATORY CONTROL IN VOCAL TREMORS
    Marshall Smith; Fiscal Year: 2002
    ..The experimental phase consists of studies of neuromuscular and respiratory input to the larynx. This information about vocal tremor will be applied to model simulations with the use of physiological signals as input model parameters. ..
  42. Patient-Oriented Models for Urinary Function in Women
    Linda Brubaker; Fiscal Year: 2008
    ..unreadable] b. To model urinary storage in health and disease [unreadable] c. To model urinary emptying in health and diseas [unreadable] [unreadable]..
  43. Ion Channels and Chemicals Controlling Synapse Stability
    Joseph McArdle; Fiscal Year: 2006
    ..The knowledge gained from this research will enlighten future molecular approaches to treating pathologies which afflict children and adults. ..
  44. Development of botulinum neurotoxin immunotherapy
    James Marks; Fiscal Year: 2007
    ..Such information will be invaluable for vaccine development as well as diagnostic testing and microbial forensics. ..
  45. Beta-2 Receptor Polymorphisms and Vasodilation in Humans
    John Eisenach; Fiscal Year: 2007
    ..My long-term career goal is to become an independent investigator performing physiology and pharmacology studies directed at the genomics of the cardiovascular system in humans. ..
  46. DIABETIC BLADDER AFFERENT NEURON AND NGF GENE THERAPY
    Michael Chancellor; Fiscal Year: 2004
    ..By defining bladder afferent neuropathy of DM, one can offer the hope of prevention, reversal, and even cure of diabetic cystopathy with NGF gene therapy. This represents a high priority in the urologic care of diabetic patients. ..
  47. Lateral Rectus Reanimation following Sixth Nerve Palsy
    Arthur Rosenbaum; Fiscal Year: 2006
    ..The final implanted device will encompass the stimulation control system, which will be optimized in individual tests within our laboratory setting. ..
  48. Randomized Trial for Botox for Urinary Incontinence
    Michael Flynn; Fiscal Year: 2006
    ..It will provide valuable data to allow for further studies on the clinical and cost-effectiveness of Botox for detrusor instability and urge urinary incontinence. ..
  49. Minimally Invasive Surgical Therapies for BPH - Treatme*
    Robert Donnell; Fiscal Year: 2005
    ..In summary, this proposal outlines what we believe to be the outstanding credentials of the Division of Urology, the Medical College of Wisconsin to serve as a clinical center in this multi-institutional trial. ..
  50. Migraine Pathophysiology:Thalamus and Extended Allodynia
    Rami Burstein; Fiscal Year: 2009
    ....
  51. Volume-Outcomes in Incontinence Surgery
    Jennifer Anger; Fiscal Year: 2005
    ..The primary outcome will be re-operation rates, repeat sling procedures (for failures), and other postoperative complications, stratified by high and low volume surgeons and hospitals. ..
  52. Novel brain stimulation to enhance stroke recovery
    Esteban Fridman; Fiscal Year: 2004
    ..In addition, it will provide some insight into mechanisms underlying such recovery. Since stroke is the leading cause of motor disabilities this work has a clear clinical relevance. ..
  53. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  54. NEUROBIOLOGY OF ANOREXIA INDUCED BY MIGRAINE PAIN
    Rami Burstein; Fiscal Year: 2004
    ..abstract_text> ..
  55. Electrophysiologic Measurements in Diabetic Neuropathy
    Joseph Arezzo; Fiscal Year: 2007
    ..If successful, these studies will result in new methods, more sensitive animal models and a better understanding of the nature, magnitude, time course, and response to therapy of functional deficits in DAN. ..
  56. MUSCLE CELLS MEDIATED GENE THERAPY FOR INCONTINENCE
    Michael Chancellor; Fiscal Year: 2005
    ..We want to underscore that these stem cells have not been obtained from embryos (animal or human) or cell lines of embryonic stem cells. ..
  57. Functional Tissue Engineering for Stress Incontinence
    Michael Chancellor; Fiscal Year: 2006
    ..These stem cells have not been obtained from embryos (animal or human) or cell lines of embryonic stem cells. ..